Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $42.91 USD
Change Today +0.67 / 1.59%
Volume 134.8K
HAE On Other Exchanges
New York
As of 2:03 PM 06/3/15 All times are local (Market data is delayed by at least 15 minutes).

haemonetics corp/mass (HAE) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/27/15 - $45.43
52 Week Low
06/12/14 - $33.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HAEMONETICS CORP/MASS (HAE)

Related News

No related news articles were found.

haemonetics corp/mass (HAE) Related Businessweek News

No Related Businessweek News Found

haemonetics corp/mass (HAE) Details

Haemonetics Corporation designs, manufactures, and markets blood management solutions. The company operates through North America Plasma, North America Blood Center and Hospital, Europe, Asia Pacific, and Japan segments. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components in the lab; and manual collection, filtration, and processing products. The company also offers hospital products comprising TEG thrombelastograph hemostasis analyzer systems that measure a patient's hemostasis or the ability to form and maintain blood clots; Cell Saver systems for cardiovascular surgeries; and OrthoPAT surgical blood salvage systems for orthopedic procedures. In addition, it provides IMPACT Online blood management portal to monitor the results of its new blood management practices; SafeTrace Tx that manages blood product inventory and transfusions, and performs patient cross-matching; BloodTrack to manage tracking and control of blood products from the hospital blood center; and SafeTrace and El Dorado Donor donation and blood unit management systems, as well as Hemasphere, Donor Doc, and e-Donor software solutions. The company markets and sells its products to bio-pharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations, and national health organizations through its direct sales force, as well as independent distributors. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.

3,383 Employees
Last Reported Date: 05/22/15
Founded in 1971

haemonetics corp/mass (HAE) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $600.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $718.0K
President of Global Plasma
Total Annual Compensation: $588.9K
Executive Vice President of Global Manufactur...
Total Annual Compensation: $455.0K
Chief Science & Technology Officer
Total Annual Compensation: $441.0K
Compensation as of Fiscal Year 2014.

haemonetics corp/mass (HAE) Key Developments

Haemonetics Corporation Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 08:30 AM

Haemonetics Corporation Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 08:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Brian P. Concannon, Chief Executive Officer, President and Director.

Haemonetics Corporation Presents at The Benchmark Company, LLC OneonOne Investor Conference, May-28-2015

Haemonetics Corporation Presents at The Benchmark Company, LLC OneonOne Investor Conference, May-28-2015 . Venue: The Pfister Hotel, 424 E. Wisconsin Avenue, Milwaukee, Wisconsin, United States.

Haemonetics Corporation Announces Board Changes

Haemonetics Corporation announced expanded roles for two executives. These changes are part of an ongoing plan to advance the company's global leadership in blood management solutions and to execute on strategies to enhance shareholder value. Kent Davies, who joined the company in 2014, is appointed to the new position of Chief Operating Officer, reporting directly to Brian Concannon, President and CEO. In this expanded role, Mr. Davies will have overall accountability for the company's commercial, product development and product management focus across the entire portfolio and in all geographies. Byron Selman, who joined the company upon the acquisition of Pall Corporation's transfusion medicine business in 2012, is appointed to the position of President, Global Markets, reporting to Mr. Davies. Mr. Selman will oversee the Company's global commercial and market development efforts, with the exception of the company's commercial Plasma business.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HAE:US $42.91 USD +0.67

HAE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cerner Corp $67.67 USD +0.53
Fresenius SE & Co KGaA €57.11 EUR -0.066
McKesson Corp $236.79 USD +0.165
Medtronic PLC $76.83 USD -0.05
Terumo Corp ¥2,758 JPY +5.00
View Industry Companies

Industry Analysis


Industry Average

Valuation HAE Industry Range
Price/Earnings 100.0x
Price/Sales 2.4x
Price/Book 2.6x
Price/Cash Flow 128.1x
TEV/Sales 1.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HAEMONETICS CORP/MASS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at